<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294319</url>
  </required_header>
  <id_info>
    <org_study_id>110078</org_study_id>
    <secondary_id>11-CH-0078</secondary_id>
    <nct_id>NCT01294319</nct_id>
  </id_info>
  <brief_title>Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men</brief_title>
  <official_title>Evaluation of Cortisol Resistance in Young Sedentary and Endurance-trained Men and Elderly Sedentary Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in
      younger endurance trained and sedentary men, and in older sedentary men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenocorticotropin (ACTH) secretion is normally exquisitely regulated through endogenous
      stimulation by corticotrophin-releasing hormone (CRH) and negative feedback inhibition by
      cortisol, resulting in a circadian rhythm of cortisol. Recent evidence suggests that older
      men, and younger men who are endurance-trained athletes, both have reduced sensitivity to
      negative feedback, and perhaps increased basal levels of cortisol and ACTH. To investigate
      these possibilities, we propose to examine multiple aspects of the
      hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in
      older sedentary men.

      Subjects will collect saliva during two evenings before additional testing, and will on the
      same evening collect urine for twelve hours, both for cortisol measurements. Blood samples
      will be collected to evaluate the response to dexamethasone. We also will assess ACTH and
      cortisol responses to medications that reduce negative inhibition of ACTH. This testing will
      occur in the evening and will include administration of the glucocorticoid antagonist
      mifepristone, the mineralocorticoid antagonist spironolactone, and/or a look-alike tablet, on
      four occasions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 24, 2011</start_date>
  <completion_date type="Actual">August 10, 2016</completion_date>
  <primary_completion_date type="Actual">August 10, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Suppressors After Dexamethasone</measure>
    <time_frame>cortisol measured between 8 and 9 after dexamethasone was taken between 11 PM and midnight</time_frame>
    <description>All subjects will take 0.25mg dexamethasone as an outpatient between 2300 and 2400h and will then report to the clinic by 0800h next day for the final visit.
At the final visit, cortisol response to dexamethasone suppression was assessed. The cortisol response was dichotomized (suppression vs. non-suppression, using 1.8 ug/dL as the cutoff point) and compared between the two groups,Sedentary Young Adults and Endurance-trained Young Athletes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-dexamethasone Cortisol Level</measure>
    <time_frame>Cortisol obtained at 8-9 AM after dexamethasone taken between 11 pm and midnight</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Cortisol Resistance</condition>
  <condition>Negative Feedback</condition>
  <condition>ACTH</condition>
  <condition>Mineralcorticoid</condition>
  <condition>Glucocorticoid</condition>
  <arm_group>
    <arm_group_label>Sedentary young adults, SMCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endurance-trained young athletes, SMCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedentary young adults, MSPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endurance-trained young athletes, MSPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedentary young adults, CPSM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endurance-trained young athletes, CPSM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedentary young adults,PCMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endurance-trained young athletes,PCMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <arm_group_label>Sedentary young adults, SMCP</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, SMCP</arm_group_label>
    <arm_group_label>Sedentary young adults, MSPC</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, MSPC</arm_group_label>
    <arm_group_label>Sedentary young adults, CPSM</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, CPSM</arm_group_label>
    <arm_group_label>Sedentary young adults,PCMS</arm_group_label>
    <arm_group_label>Endurance-trained young athletes,PCMS</arm_group_label>
    <other_name>Mifepristone 400 MG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sedentary young adults, SMCP</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, SMCP</arm_group_label>
    <arm_group_label>Sedentary young adults, MSPC</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, MSPC</arm_group_label>
    <arm_group_label>Sedentary young adults, CPSM</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, CPSM</arm_group_label>
    <arm_group_label>Sedentary young adults,PCMS</arm_group_label>
    <arm_group_label>Endurance-trained young athletes,PCMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <arm_group_label>Sedentary young adults, SMCP</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, SMCP</arm_group_label>
    <arm_group_label>Sedentary young adults, MSPC</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, MSPC</arm_group_label>
    <arm_group_label>Sedentary young adults, CPSM</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, CPSM</arm_group_label>
    <arm_group_label>Sedentary young adults,PCMS</arm_group_label>
    <arm_group_label>Endurance-trained young athletes,PCMS</arm_group_label>
    <other_name>Spironolactone 200 MG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined</intervention_name>
    <arm_group_label>Sedentary young adults, SMCP</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, SMCP</arm_group_label>
    <arm_group_label>Sedentary young adults, MSPC</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, MSPC</arm_group_label>
    <arm_group_label>Sedentary young adults, CPSM</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, CPSM</arm_group_label>
    <arm_group_label>Sedentary young adults,PCMS</arm_group_label>
    <arm_group_label>Endurance-trained young athletes,PCMS</arm_group_label>
    <other_name>Mifepristone 400 MG and Spironolactone 200 MG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Sedentary young adults, SMCP</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, SMCP</arm_group_label>
    <arm_group_label>Sedentary young adults, MSPC</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, MSPC</arm_group_label>
    <arm_group_label>Sedentary young adults, CPSM</arm_group_label>
    <arm_group_label>Endurance-trained young athletes, CPSM</arm_group_label>
    <arm_group_label>Sedentary young adults,PCMS</arm_group_label>
    <arm_group_label>Endurance-trained young athletes,PCMS</arm_group_label>
    <other_name>Dexamethasone 0.25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Men aged 18 to 30 years of age are required for the young endurance trained and sedentary
        groups; men aged 65-80 years for the older study group, who will meet criteria for
        sedentary men below. Women and children are excluded to enhance homogeneity of responses
        and avoid the influence of menstrual cyclicity on the HPA axis.

        Sedentary:

          -  Less than one hour physical activity per week for three years

          -  No change in exercise anticipated for 6 weeks

        Trained:

          -  Greater than 45km (28 miles) running per week for at least 3 months

          -  No change in exercise anticipated for 6 weeks

        For all participants:

          -  All races

          -  Sleep-wake cycle with sleeping at night, wakening between 5 and 8 AM

          -  BMI between 18 and 25 kg/M2

          -  Normal TSH and free T4

        EXCLUSION CRITERIA:

        For all participants:

          -  Sleep disorders as assessed by sleep apnea questionnaire

          -  Smoking

          -  No more than 2 servings of alcohol daily

          -  Medications known to affect the HPA axis or steroid metabolism, including narcotics,
             Glucocorticoids, megace or CYP3A4 modulators

          -  History of psychiatric or endocrine disorders

          -  Marijuana or other illicit drug use

          -  Recent appendicular or skeletal injury

          -  Uncontrolled hypertension

          -  Chronic pain requiring daily medication

          -  Current treatment with medications related to mineralocorticoid function such as
             potassium, ACE-inhibitors, ARBs, diuretics, spironolactone

          -  Frailty score of 4-7 on the Canadian Study of Health and Aging frailty scale (Rockman
             2005)

          -  Overtraining syndrome will be an exclusion and will be assessed by questionnaire

          -  Abnormal creatinine level (greater than 1.2 mg/dl)

          -  Liver function tests greater than two fold normal

          -  Benzodiazepine use
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynnette K Nieman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-CH-0078.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Bauer ME. Stress, glucocorticoids and ageing of the immune system. Stress. 2005 Mar;8(1):69-83. Review.</citation>
    <PMID>16019599</PMID>
  </reference>
  <reference>
    <citation>Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab. 1984 Jul;59(1):25-8.</citation>
    <PMID>6327758</PMID>
  </reference>
  <reference>
    <citation>Booth CK, Probert B, Forbes-Ewan C, Coad RA. Australian army recruits in training display symptoms of overtraining. Mil Med. 2006 Nov;171(11):1059-64.</citation>
    <PMID>17153542</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <results_first_submitted>August 11, 2017</results_first_submitted>
  <results_first_submitted_qc>October 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2017</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cortical Resistance</keyword>
  <keyword>ACTH</keyword>
  <keyword>Glucocorticoid</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>SPIRONOLACTONE</keyword>
  <keyword>Exercise</keyword>
  <keyword>Hypothalamic-Pituitary-Adrenal Axis</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sedentary Young Adults, SMCP</title>
          <description>Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone</description>
        </group>
        <group group_id="P2">
          <title>Endurance-trained Young Athletes, SMCP</title>
          <description>Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone</description>
        </group>
        <group group_id="P3">
          <title>Sedentary Young Adults, MSPC</title>
          <description>Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone</description>
        </group>
        <group group_id="P4">
          <title>Endurance-trained Young Athletes, MSPC</title>
          <description>Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone</description>
        </group>
        <group group_id="P5">
          <title>Sedentary Young Adults, CPSM</title>
          <description>Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone</description>
        </group>
        <group group_id="P6">
          <title>Endurance-trained Young Athletes, CPSM</title>
          <description>Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone</description>
        </group>
        <group group_id="P7">
          <title>Sedentary Young Adults,PCMS</title>
          <description>Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
        </group>
        <group group_id="P8">
          <title>Endurance-trained Young Athletes,PCMS</title>
          <description>Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sedentary Young Adults, SMCP</title>
          <description>Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone</description>
        </group>
        <group group_id="B2">
          <title>Endurance-trained Young Athletes, SMCP</title>
          <description>Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone</description>
        </group>
        <group group_id="B3">
          <title>Sedentary Young Adults, MSPC</title>
          <description>Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone</description>
        </group>
        <group group_id="B4">
          <title>Endurance-trained Young Athletes, MSPC</title>
          <description>Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone</description>
        </group>
        <group group_id="B5">
          <title>Sedentary Young Adults, CPSM</title>
          <description>Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone</description>
        </group>
        <group group_id="B6">
          <title>Endurance-trained Young Athletes, CPSM</title>
          <description>Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone</description>
        </group>
        <group group_id="B7">
          <title>Sedentary Young Adults,PCMS</title>
          <description>Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
        </group>
        <group group_id="B8">
          <title>Endurance-trained Young Athletes,PCMS</title>
          <description>Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.57" spread="0.99"/>
                    <measurement group_id="B2" value="25.01" spread="1.58"/>
                    <measurement group_id="B3" value="24.2" spread="2.33"/>
                    <measurement group_id="B4" value="25.2" spread="1.79"/>
                    <measurement group_id="B5" value="23.3" spread="2.97"/>
                    <measurement group_id="B6" value="24.5" spread="4.22"/>
                    <measurement group_id="B7" value="27.8" spread="3.06"/>
                    <measurement group_id="B8" value="23.6" spread="4.01"/>
                    <measurement group_id="B9" value="24.73" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="4.33"/>
                    <measurement group_id="B2" value="24.0" spread="3.27"/>
                    <measurement group_id="B3" value="23.7" spread="3.04"/>
                    <measurement group_id="B4" value="22.3" spread="1.89"/>
                    <measurement group_id="B5" value="24.2" spread="2.75"/>
                    <measurement group_id="B6" value="24.1" spread="1.10"/>
                    <measurement group_id="B7" value="23.4" spread="2.98"/>
                    <measurement group_id="B8" value="22.8" spread="2.00"/>
                    <measurement group_id="B9" value="23.53" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Fat Percent</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="6.90"/>
                    <measurement group_id="B2" value="20.2" spread="5.16"/>
                    <measurement group_id="B3" value="25.2" spread="5.11"/>
                    <measurement group_id="B4" value="19.5" spread="1.99"/>
                    <measurement group_id="B5" value="23.2" spread="5.82"/>
                    <measurement group_id="B6" value="19.7" spread="5.15"/>
                    <measurement group_id="B7" value="24.4" spread="5.16"/>
                    <measurement group_id="B8" value="16.8" spread="4.04"/>
                    <measurement group_id="B9" value="21.33" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.28" spread="8.05"/>
                    <measurement group_id="B2" value="16.73" spread="5.60"/>
                    <measurement group_id="B3" value="19.13" spread="4.80"/>
                    <measurement group_id="B4" value="14.70" spread="3.19"/>
                    <measurement group_id="B5" value="19.21" spread="8.69"/>
                    <measurement group_id="B6" value="15.13" spread="3.79"/>
                    <measurement group_id="B7" value="17.64" spread="4.31"/>
                    <measurement group_id="B8" value="13.69" spread="4.56"/>
                    <measurement group_id="B9" value="16.61" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Suppressors After Dexamethasone</title>
        <description>All subjects will take 0.25mg dexamethasone as an outpatient between 2300 and 2400h and will then report to the clinic by 0800h next day for the final visit.
At the final visit, cortisol response to dexamethasone suppression was assessed. The cortisol response was dichotomized (suppression vs. non-suppression, using 1.8 ug/dL as the cutoff point) and compared between the two groups,Sedentary Young Adults and Endurance-trained Young Athletes.</description>
        <time_frame>cortisol measured between 8 and 9 after dexamethasone was taken between 11 PM and midnight</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endurance-trained Young Athletes</title>
            <description>Endurance-trained Young Athletes group consists of 20 subjects, each subject was randomized to one of the following four arms:
Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone
Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone
Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone
Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Sedentary Young Adults</title>
            <description>Sedentary young adults group consists of 19 subjects, each subject was randomized to one of the following four arms:
Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone
Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone
Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone
Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Suppressors After Dexamethasone</title>
          <description>All subjects will take 0.25mg dexamethasone as an outpatient between 2300 and 2400h and will then report to the clinic by 0800h next day for the final visit.
At the final visit, cortisol response to dexamethasone suppression was assessed. The cortisol response was dichotomized (suppression vs. non-suppression, using 1.8 ug/dL as the cutoff point) and compared between the two groups,Sedentary Young Adults and Endurance-trained Young Athletes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4872</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dexamethasone Cortisol Level</title>
        <time_frame>Cortisol obtained at 8-9 AM after dexamethasone taken between 11 pm and midnight</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endurance-trained Young Athletes</title>
            <description>Endurance-trained young athletes group consists of 20 subjects, each subject was randomized to one of the following four arms:
Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone
Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone
Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone
Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Sedentary Young Adults</title>
            <description>Sedentary young adults group consists of 19 subjects, each subject was randomized to one of the following four arms:
Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone
Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone
Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone
Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dexamethasone Cortisol Level</title>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.98" spread="5.92"/>
                    <measurement group_id="O2" value="9.98" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2786</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sedentary Young Adults</title>
          <description>Sedentary young adults group consists of 19 subjects, each subject was randomized to one of the following four arms:
Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
        </group>
        <group group_id="E2">
          <title>Atheletes</title>
          <description>Endurance-trained Young Athletes group consists of 20 subjects, each subject was randomized to one of the following four arms:
Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lynnette Nieman</name_or_title>
      <organization>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</organization>
      <phone>301-496-4000</phone>
      <email>niemanl@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

